Selected publications
-
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: Phase 1 results and long-term follow-up.
Blood.
2018
Academic Article
GET IT
Times cited: 1 -
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
The lancet oncology.
2017
Academic Article
GET IT
Times cited: 31 -
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Blood.
2017
Academic Article
GET IT
Times cited: 9 -
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
Blood.
2017
Conference Paper
GET IT
Times cited: 15 -
The european hematology association roadmap for european hematology research: A consensus document.
Haematologica.
2016
Academic Article
GET IT
Times cited: 19 -
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: Final results from a pivotal study.
Haematologica.
2015
Article
GET IT
Times cited: 13 -
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
Journal of Clinical Oncology.
2012
Academic Article
GET IT
Times cited: 172 -
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
Blood.
2009
Academic Article
GET IT
Times cited: 31